By pairing robust artificial enzymes with highly selective aptamers, nanozyme aptasensors could help detect disease biomarkers, pathogens, and contaminants faster, but the review shows that real-world deployment still depends on overcoming matrix interference, biofouling, and manufacturing challenges.
The review highlights selected nanozyme aptasensor examples that can detect specific targets at concentrations as low as 7.5 pg/mL, although comparisons with earlier systems, such as those with detection limits of 1 nM, should be interpreted cautiously because they involve different targets, units, and assay architectures. Their sensitivity, robustness, and potential scalability make them promising candidates for point-of-care diagnostics and environmental monitoring, where they could support the detection of trace contaminants and disease biomarkers in complex samples.

The comparison between aptamers and antibodies, two commonly used MREs or bioreceptors, during biosensor development. Image Credit: Adapted from Weerathunge, P., Bagree, G., Mahasivam, S., Amarasinghe, E., Ramanathan, R., & Bansal, V. (2026). Advancing nanozyme aptasensors status quo via strategies and key fabrication considerations. Npj Biosensing. DOI:10.1038/s44328-026-00110-0 using ChatGPT / Oen AI
Addressing the Shortcomings of Natural Enzymes
Traditional biosensors rely heavily on natural enzymes due to their high specificity and fast catalytic activity. However, these enzymes can be expensive to produce, require complex purification processes, and lose activity when exposed to heat or varying environmental conditions. Their limited stability complicates long-term storage and field use.
To address these challenges, researchers have developed nanozymes, synthetic nanomaterials that mimic the catalytic activity of natural enzymes. They can be composed of materials such as noble metals, metal oxides, carbon nanomaterials, and metal-organic frameworks. Compared to natural enzymes, nanozymes offer greater stability, longer shelf life, lower storage requirements, and more consistent large-scale production.
Diverse Architectures of Nanozyme Aptasensors
Nanozyme aptasensors can be constructed by attaching synthetic single-stranded DNA or RNA receptors to the surface of nanozymes. These aptamers are often selected through the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process, which identifies sequences that bind strongly and specifically to targets ranging from small molecules to whole cells. Because aptamers are chemically synthesized, they exhibit minimal batch-to-batch variation and are less expensive to produce than antibodies.
Researchers categorized nanozyme aptasensors into three main designs. The first is the nanozyme and aptamer-based immunosorbent assay (NAISA). In this format, a capture probe immobilized on a microtiter plate binds the target, while a second aptamer linked to a nanozyme generates the detection signal through a sandwich structure.
The second design is adsorption/desorption-based sensors, which are label-free approaches that rely on the reversible adsorption of aptamers onto the nanozyme surface. Upon target binding, the aptamer undergoes a conformational change or detaches from the surface, exposing or blocking the nanozyme’s active sites and switching the catalytic signal.
The third format is amplification-based systems, which combine nanozymes with nucleic acid amplification methods to improve sensitivity. Techniques, including loop-mediated isothermal amplification (LAMP), catalytic hairpin assembly (CHA), hybridization chain reaction (HCR), and polymerase chain reaction (PCR), are integrated with nanozyme readouts to amplify nucleic acid recognition or signal output. This enables the detection of very low concentrations of target molecules. The review emphasizes that these formats involve trade-offs: NAISA offers high specificity, adsorption/desorption formats offer simpler, label-free operation, and amplification-based systems offer higher sensitivity at the cost of greater complexity.
Sensitivity and Performance Metrics
The review traces the evolution of nanozyme aptasensors over the past decade. Recent designs have significantly enhanced sensitivity, exemplified by a representative hybrid nanoprobe for cardiac troponin I that achieved a detection limit of 7.5 pg/mL with a linear range of 0.01-100 ng/mL. These advancements have been driven by improved control over sensor architecture, including the use of DNA nanotetrahedra that enhance target accessibility, although this cardiac troponin I system also involved horseradish peroxidase (HRP) and DNAzyme co-catalysis rather than a nanozyme-only readout.
Implications for Diagnostics and Environmental Monitoring
Nanozyme aptasensors have significant implications for clinical diagnostics, food safety, and environmental monitoring. Their high stability and straightforward operation make them promising for field testing, where conventional enzyme-based sensors often underperform, although practical deployment remains an active development challenge.
In food safety, paper-based sensors made from carbon nitride and copper oxide nanomaterials can detect Salmonella typhimurium in as little as six minutes. Other platforms identify foodborne pathogens, including Listeria monocytogenes, and detect pesticides such as acetamiprid and chlorpyrifos in samples such as water, milk, and fruit juice.
In clinical diagnostics, nanozyme aptasensors have been reported for detecting biomarkers such as cardiac troponin I and mucin 1, with potential relevance for earlier cardiovascular disease and cancer diagnostics. Reported environmental monitoring platforms have used these sensors to measure metal ions, such as Hg2+, and pesticide and antibiotic contaminants, including kanamycin.
Future Directions and Technological Integration
In summary, the next step for nanozyme aptasensors is to translate laboratory designs into practical point-of-care devices. Microfluidic systems, printable paper-based sensors, and label-free formats offer simple, low-cost platforms for field testing. However, widespread use will require better control of biofouling, matrix interference, and changes in nanozyme activity when testing complex clinical or environmental samples.
The review also highlights the growing prospective role of artificial intelligence (AI) and machine learning (ML) in sensor development. These tools could help predict aptamer-nanozyme interactions and optimize signal amplification strategies. Advancements in materials engineering, sensor design, and computational modeling could support the large-scale production of portable nanozyme aptasensors for healthcare, environmental monitoring, and food safety.
- Weerathunge, P., Bagree, G., Mahasivam, S., Amarasinghe, E., Ramanathan, R., & Bansal, V. (2026). Advancing nanozyme aptasensors status quo via strategies and key fabrication considerations. npj Biosensing. DOI: 10.1038/s44328-026-00110-0, https://www.nature.com/articles/s44328-026-00110-0
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]















